Global Human Insulin Market is expected to grow at CAGR of 12.10% to reach USD 90,812.40 Million till 2025. Human insulin in the report refers to synthetic insulin manufactured in laboratories by increasing insulin protein with the help of e. coli bacteria. Human insulin can be administered orally or through insulin infusion devices. Some conventional insulin infusion devices are syringes, injection pens, and insulin pumps. These devices are used to deliver insulin on time and regularly.

Increasing prevalence of diabetes, rising obesity endemic, rise in geriatric population, and increasing awareness among people about diabetic care and technological advancement in delivery devices of insulin are some of the factors influencing the growth of the human insulin market. However, strict regulatory requirements for approval of insulin and high cost of insulin analog inhibit the growth of the human insulin market.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/951 

Market Dynamics

The increasing affordability of human insulin is one of the key factors driving the human insulin market. In May 2019, Eli Lilly and Company launched Insulin Lispro Injection for people who use Lilly's rapid-acting insulin and need a lower-cost option. Insulin Lispro Injection has a 50% lower price than its identical medicine, Humalog U-100 (insulin lispro injection).

Increasing diabetic population is also strongly impacting the growth of the market. Diabetes is a chronic and non-communicable disease, and its global prevalence is rising enormously. Nowadays, it is one of the leading causes of death and has an increased risk of developing several serious health problems. It is the primary cause of cardiovascular diseases, kidney diseases, eye disorders, and strokes.

As per 2017, National Diabetes Statistic Report suggested by the Centers for Disease Control and Prevention, more than 100 million people in the US have diabetes or prediabetes.

Segmentation

Based on type, the global human insulin market has been segmented into traditional human insulin and modern human insulin. Traditional human insulin segment includes premixed traditional, intermediate-acting, and short-acting. Modern human insulin segment includes premixed modern, long-acting, and rapid-acting. Modern human insulin was the leading segment in 2018. Modern human insulin, also known as analog insulin, is prescribed by physicians for the treatment of diabetes. It is the customized form of traditional human insulin and provides effective results in comparison to traditional human insulin.

The global human insulin market, by brand, has been segmented into Lantus, Novorapid, Humalog, Novomix, Levemir, Apidar, Humulin, and Insuman. Lantus is a long-acting human insulin analog, and it is available in more than 120 countries. Among all the brands, Lantus commands the largest share in the human insulin market. Apidra is a rapid acting human insulin analog. Also, Apidra and Levemir are the fastest growing brand in the human insulin market. Moreover, there are various drugs in the pipeline, which would have a positive impact on the growth of the market in the coming years.

Regional Analysis

The global human insulin market has been categorized as the Americas, Europe, Asia-Pacific, and Middle East & Africa.

The Americas dominate the global human insulin market, owing to the growing old age population, increasing healthcare awareness, rising prevalence of diabetes, improvement in reimbursement policies, and increasing clinical trials driving the growth of human insulin.

The European Human Insulin market has been segmented into Western Europe and Eastern Europe. In 2018, Europe stood second in the global Human Insulin market. Increasing focus on the treatment of diabetes and rising clinical trials by market players will support the growth of Europe Human Insulin market. For instance, a France-based firm, Adocia received positive topline pharmacodynamic and safety results from the first Phase 1 study of ADO09. ADO09 is intended to improve postprandial glucose control and long-term outcomes for people requiring prandial insulin treatment.

Asia-Pacific is expected to register the highest CAGR during the forecast period. Companies are introducing new advanced products in this region, which is boosting Asia-Pacific human insulin market. In March 2018, Biocon Ltd and Mylan NV received approval for biosimilar insulin glargine Semglee 100 IU/mL 3 mL prefilled pen from the Therapeutic Goods Administration (TGA) Australia.

On the other hand, the Middle East & Africa holds the least share in the global human insulin market due to the low economic development, especially within the African region.

Key Players

The prominent players in the global human insulin market are ADOCIA, MERCK & CO., INC., Julphar, Pfizer Inc., Bristol-Myers Squibb Company, GLAXOSMITHKLINE PLC, SANOFI, Oramed, Novo Nordisk India Pvt. Ltd, Eli Lilly and Company, BIOCON, and Tonghua Dongbao Pharmaceutical Co., Ltd.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/human-insulin-market-951 

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com